Prophase Labs Inc (NASDAQ:PRPH)
| 7.67 Delayed Data As of Mar 31 |  +0.21 / +2.82%Today’s Change | 6.31 Today|||52-Week Range 15.25 | -20.35% Year-to-Date |
Latest PRPH News | Press Releases
| ProPhase Labs, Inc. (PRPH) Reports Q4 Loss, Tops Revenue Estimates Mar 28 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 7.46 |
| Today’s open | 7.60 |
| Day’s range | 7.55 - 7.72 |
| Volume | 920 |
| Average volume (3 months) | 53,032 |
| Market cap | $132.0M |
Data as of 4:00pm ET, 03/31/2023
Growth & Valuation
| Earnings growth (last year) | +181.79% |
| Earnings growth (this year) | -97.55% |
| Earnings growth (next 5 years) | +1.00% |
| Revenue growth (last year) | +55.17% |
| P/E ratio | 7.5 |
| Price/Sales | 1.46 |
| Price/Book | 1.96 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| EPIXESSA Pharma Inc | 0.00 | 0.00% |
| MISTMilestone Pharmaceut... | +0.15 | +3.92% |
| EYENEyenovia Inc | +0.36 | +11.32% |
| MDWDMediwound Ltd | +0.22 | +1.66% |
Data as of 4:00pm ET, 03/31/2023
Financials
| Next reporting date | May 16, 2023 |
| EPS forecast (this quarter) | -$0.09 |
| Annual revenue (last year) | $122.6M |
| Annual profit (last year) | $18.5M |
| Net profit margin | 15.05% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
No executives to display |
Corporate headquarters Garden City, New York |
Forecasts
